In a mouse clinical trial consisting of multiple patient- and cell line-derived xenograft models of KRASG12C NSCLC, RMC-6291 outperformed adagrasib, a KRASG12C(OFF) inhibitor, by increasing the number of responses, the depth of tumor regressions, and the durability of responses.Combination ...
“We are pleased to report encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors that are providing strong validation of our RAS(ON) Inhibitor platform broadly. The RMC-6236 safety data support that this highly innovative, oral RASMULTI Inhibi...
体内:RMC-6291 (200mg/kg, 口服, 每日一次, 60天) 在小鼠肿瘤模型中显著抑制肿瘤生长并诱导免疫记忆[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Clinical Trial 参考文献: [1]. Nichols R J, et al. RMC-6291, a next-generation tri-comple...